ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	6 Months Ended			6 Months Ended																0 Months Ended
	Jun. 30, 2014 item	Dec. 31, 2013	Dec. 31, 2013 Restatement	Jun. 30, 2014 Minimum	Jun. 30, 2014 Minimum Managed Care Rebates	Jun. 30, 2014 Minimum Medicare Part D Coverage Gap Rebates	Jun. 30, 2014 Maximum	Jun. 30, 2014 Maximum Managed Care Rebates	Jun. 30, 2014 Maximum Medicare Part D Coverage Gap Rebates	Jun. 30, 2014 Gralise Minimum	Jun. 30, 2014 Gralise Maximum	Jun. 30, 2014 Zipsor	Jun. 30, 2014 CAMBIA Minimum	Jun. 30, 2014 CAMBIA Maximum	Jun. 30, 2014 Lazanda Minimum	Jun. 30, 2014 Lazanda Maximum	Jun. 30, 2014 500mg Glumetza	Jun. 30, 2014 1000mg Glumetza Minimum	Jun. 30, 2014 1000mg Glumetza Maximum	Oct. 18, 2013 Liability related to sale of future royalties PDL BioPharma
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of product candidates under clinical development	1
Summary Of Significant Accounting Policies
Royalty and milestone payments received																				$ 240,500,000
Accounts payable and accrued liabilities	44,274,000	34,935,000	(6,900,000)
Liability related to the sale of future royalties and milestones	$ 66,641,000	$ 56,357,000	$ 6,900,000
Product return period prior to expiration							6 months
Period after expiration for accepting unsalable product							12 months
Product shelf-life										24 months	36 months	36 months	24 months	48 months	24 months	36 months	48 months	24 months	36 months
Discount taken off period after the quarter in which product shipped to the customer				1 month			2 months
Cash discount (as a percent)	2.00%
Discount reimbursement period after filling of prescription subject to discount	1 month
Period after the quarter in which prescription is filled for paying rebate				2 months			3 months
Period after the quarter in which prescription is filled for rebate					1 month	2 months		3 months	3 months